Arnold, D., Cervantes, A., Ducreux, M. P., Han, S., Lenz, H., Muro, K., Raghav, K. P. S., Shen, L., Wang, C., Voon, P. J., Hsu, H., Xia, B., Iwasawa, R., Carrigan, S., Diorio, B., Lorenzini, P. A., Acharya, S., Sethi, S. N., Baig, M., Pietrantonio, F. (2025). OrigAMI-2: A randomized, phase 3 study of amivantamab vs cetuximab, both in combination with FOLFOX or FOLFIRI, as first-line treatment in left-sided
            <i>RAS</i>
            /
            <i>BRAF</i>
            wild-type metastatic colorectal cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps3636